American Journal of Health-System Pharmacy最新文献

Purpose: Black persons comprise 13.4% of the US population but represent 36% of those with kidney failure. Medication-related disparities likely contribute to these outcomes. Patient perspective provides valuable insight into what they need and want from their medications and their care.

Methods: We conducted five 1.25-hour online focus group sessions via a videoconferencing app between March 30 and June 27, 2022. Our nationally recruited sample consisted of 19 adults 37 to 72 years of age who represented a broad range of educational backgrounds, all with CKD (non-dialysis-dependent, dialysis-dependent, or post kidney transplant). Semistructured guides were constructed by our team and used by moderators. Inductive thematic analysis procedures were followed. Patients representative of our study population were integral members of our research team.

Results: Our analysis includes 3 major themes and associated subthemes: (1) meet patients where they are (subthemes: patient autonomy and empowerment, experience with illness, home and community support, barriers to understanding, and barriers to access; (2) the patient journey with medications (subthemes: fears with medications, frustrations and burdens with medication use, adjusting to medications, desire for awareness and explanation, preferences with medications, and helpful tools and supports; and (3) significant interactions with healthcare professionals (subthemes: barriers to building trust, type of care and interactions desired, and care team communication).

Conclusion: Recognizing the patient as an individual, addressing their frustrations and needs with medications, and attending to implicit biases and strategies to overcome barriers and empower Black persons with CKD are anticipated to reduce medication- related disparities and improve health outcomes experienced by this population.

Purpose: The Advancing Kidney Health through Optimal Medication Management (AKHOMM) initiative was developed with the vision that every person with kidney disease receives optimal medication management through team-based care including a pharmacist to improve kidney health. Due to the need for education and clinical practice implementation strategies, the AKHOMM initiative designed 2 educational programs to help achieve our vision: a continuing education curriculum and a learning and action collaborative (LAC).

Summary: The curriculum is online, interactive, and case based, with interprofessional accreditation, to provide baseline competency in comprehensive medication management (CMM) across chronic kidney disease and address health disparities in this population. The development process involved an interprofessional approach with input from persons with kidney disease and care partners. Modules have been well received based on postactivity surveys, with over 90% of respondents (970/1,044) indicating that the activity will improve their ability to treat and manage their patients. Ongoing quality assurance of existing modules, coupled with development of new modules in prioritized areas (cardiovascular-kidney-metabolic [CKM] syndrome, glomerular diseases) will continue to provide education to the pharmacy and broader healthcare communities. The LAC was designed using implementation science principles to facilitate pharmacist inclusion in patient care teams to provide CMM to patients with CKM. Site teams will include a pharmacist, provider champion, and others coupled with an implementation coach and field expert. Through a continuous quality improvement framework, the teams will work towards achieving their bold aim over a 12-month implementation period.

Conclusion: The curriculum and LAC address the current void of pharmacist-based care in CKM.

Purpose: An estimated 37 million people currently live with chronic kidney disease in the US, which places them at increased risk for kidney disease progression, cardiovascular disease, and mortality. This review discusses current standard-of-care management of patients with chronic kidney disease, identifies key gaps in care, and briefly highlights how pharmacists can address gaps in care as members of the multidisciplinary care team.

Summary: Recent advances in guideline-directed medical therapies for patients with chronic kidney disease, including agents from the sodium-glucose cotransporter, glucagon-like peptide-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist classes, can dramatically improve cardiovascular-kidney-metabolic care and outcomes. Unfortunately, gaps in screening, diagnosis, and implementation of recommended therapies persist. Team-based models of care-inclusive of the person with chronic kidney disease-have the potential to significantly improve care and outcomes for people with chronic kidney disease by addressing current gaps in care.

Conclusion: As members of the multidisciplinary care team, pharmacists can play a critical role in addressing current gaps in care, including optimized use of guideline-directed medical therapies, in patients with chronic kidney disease.

Purpose: To review the key updates in the 2024 KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease (CKD) and highlight the essential role of pharmacists in implementing these recommendations.

Summary: The updated guideline introduces significant changes in CKD management, including the use of validated equations for estimating glomerular filtration rate (GFR) for drug dosing, with incorporation of serum cystatin C into GFR estimates for specific patient populations, and an emphasis on a comprehensive approach to delay disease progression. The guideline recommends sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy for kidney disease with proteinuria, with or without diabetes, renin-angiotensin-aldosterone system inhibitors (RAASi) blood pressure control and proteinuria management, and statins to reduce the risk of atherosclerotic cardiovascular disease. New evidence supports the use of finerenone in patients with type 2 diabetes and CKD, and GLP-1 receptor agonists for their kidney-protective effects. The guidelines also emphasize the importance of nephrotoxin stewardship and prevention of acute kidney injury through patient education on sick day medication management.

Conclusion: Pharmacists play a crucial role in implementing these updated guidelines through comprehensive medication management, nephrotoxin stewardship, drug dosing adjustments, and patient education. Their involvement in interprofessional care teams is essential for optimizing health outcomes in patients with CKD.

Purpose: To describe how pharmacists can enhance the care of individuals with chronic kidney disease by examining the role of the pharmacist in new care models.

Summary: The implications of chronic kidney disease for the healthcare system, particularly for the Centers for Medicare and Medicaid Services, are profound. New payment models and the development of medications that slow progression of kidney disease are transforming the landscape of nephrology care in the US. Pharmacists can play a pivotal role as part of the interdisciplinary care team to optimize medication therapy for this population. In particular, the Kidney Care Choices value-based care model is encouraging a more holistic approach to managing kidney disease that aligns with the goals of comprehensive medication management by pharmacists. Pharmacists can leverage fee-for-service and value-based care reimbursement models in primary care and nephrology care settings to successfully implement guideline-directed medical therapy for patients with chronic kidney disease.

Conclusion: The changing landscape of nephrology offers many opportunities for pharmacists to enhance patient care. More studies are needed to demonstrate the cost-effectiveness of pharmacists in this specialty to promote the expansion and impact of this role.